Skip to content
2000
Volume 20, Issue 3
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Background

Emerging studies have reported the potential anticancer activity of FDA-approved benzimidazole-based anthelmintics against lung cancer. Therefore, the current systematic review aimed to explore the anticancer activity of benzimidazole-based anthelmintics in lung cancer animal models.

Methods

The databases including Pubmed, ScienceDirect, and Google Scholar were searched till April 2024 for the animal studies evaluating the anticancer activity of benzimidazole-based anthelmintics against lung cancer. The relevant data was extracted in the prepared format in Microsoft Excel. Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk of bias (RoB) was used to assess the quality of included studies. The protocol for this study has been registered in PROSPERO (Registration number: ).

Results

Initially, we obtained 4150 articles, and finally eight articles were included in the current study. The information in the included studies was a bit diversified including different benzimidazole-based anthelmintics, dosage, route of administration, and duration of experiments. However, all studies reported that exposure to benzimidazole-based anthelmintics decreased tumor size and tumor volume in animal models of lung cancer.

Conclusion

In conclusion, benzimidazole-based anthelmintics have the potential to treat lung cancer. However, more controlled and thorough preclinical studies are required to evaluate its efficacy, safety, and mechanism of anticancer activities.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863308476240702053700
2024-07-15
2025-09-01

  • From This Site

    /content/journals/cds/10.2174/0115748863308476240702053700
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. O’DowdE. MackenzieJ. BalataH. Lung cancer for the non-respiratory physician.Clin. Med. 2021216e578e58310.7861/clinmed.2021‑0657 34862216
     [Google Scholar]
  2. DidkowskaJ. WojciechowskaU. MańczukM. ŁobaszewskiJ. Lung cancer epidemiology: Contemporary and future challenges worldwide.Ann. Transl. Med.20164815010.21037/atm.2016.03.11 27195268
     [Google Scholar]
  3. FerlayJ. SoerjomataramI. DikshitR. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012.Int. J. Cancer20151365E359E38610.1002/ijc.29210 25220842
     [Google Scholar]
  4. SinghN. AgrawalS. JiwnaniS. Lung cancer in India.J. Thorac. Oncol.20211681250126610.1016/j.jtho.2021.02.004 34304854
     [Google Scholar]
  5. SimoneC.B.II BurriS.H. HeinzerlingJ.H. Novel radiotherapy approaches for lung cancer: Combining radiation therapy with targeted and immunotherapies.Transl. Lung Cancer Res.20154554555210.3978/J.ISSN.2218‑6751.2015.10.05 26629423
     [Google Scholar]
  6. AraghiM. MannaniR. Recent advances in non-small cell lung cancer targeted therapy; an update review.Cancer Cell Int.202324116210.1186/s12935‑023‑02990‑y
     [Google Scholar]
  7. UpretyD. WestH.J. Perioperative therapy for resectable non-small-cell lung cancer: Weighing options for the present and future.JCO Oncol. Pract.202319740340910.1200/OP.23.00014 37023371
     [Google Scholar]
  8. PanZ. LiuH. ChenJ. [Lung cancer stem-like cells and drug resistance]. Zhongguo Fei Ai Za Zhi202225211111710.3779/J.ISSN.1009‑3419.2022.102.02 35224964
     [Google Scholar]
  9. ZhouF. DuJ. WangJ. Albendazole inhibits HIF-1α-dependent glycolysis and VEGF expression in non-small cell lung cancer cells.Mol. Cell. Biochem.20174281-217117810.1007/s11010‑016‑2927‑3 28063005
     [Google Scholar]
  10. PatelK. DoudicanN.A. SchiffP.B. OrlowS.J. Albendazole sensitizes cancer cells to ionizing radiation.Radiat. Oncol.20116116010.1186/1748‑717X‑6‑160 22094106
     [Google Scholar]
  11. DograN. MukhopadhyayT. Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: A novel antiproliferative agent with a potential therapeutic implication.J. Biol. Chem.201228736306253064010.1074/jbc.M111.324228 22745125
     [Google Scholar]
  12. DograN. KumarA. MukhopadhyayT. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways.Sci. Rep.2018811192610.1038/s41598‑018‑30158‑6 30093705
     [Google Scholar]
  13. LaudisiF. MarônekM. Di GraziaA. Repositioning of anthelmintic drugs for the treatment of cancers of the digestive system.Int. J. Mol. Sci.20202114495710.3390/ijms21144957
     [Google Scholar]
  14. GargA. KarhanaS. BanoA. Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer.J. Biomol. Struct. Dyn.202312210.1080/07391102.2023.2258419 37740654
     [Google Scholar]
  15. GargA. KaityS. ThakurM. Future prospective and challenges in the treatment of cancer.Therapeutic Nanocarriers in Cancer Treatment: Challenges and Future Perspective.Sharjah, United Arab EmiratesBentham Science Publishers202338239410.2174/9789815080506123010016
     [Google Scholar]
  16. MoherD. LiberatiA. TetzlaffJ. AltmanD.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.PLoS Med.200967e100009710.1371/journal.pmed.1000097 19621072
     [Google Scholar]
  17. HooijmansC.R. RoversM.M. de VriesR.B.M. LeenaarsM. Ritskes-HoitingaM. LangendamM.W. SYRCLE’s risk of bias tool for animal studies.BMC Med. Res. Methodol.20141414310.1186/1471‑2288‑14‑43 24667063
     [Google Scholar]
  18. ZengX. ZhangY. KwongJ.S.W. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta‐analysis, and clinical practice guideline: A systematic review.J. Evid. Based Med.20158121010.1111/jebm.12141 25594108
     [Google Scholar]
  19. PageM.J. McKenzieJ.E. BossuytP.M. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.BMJ202137271n7110.1136/bmj.n71 33782057
     [Google Scholar]
  20. de Souza GonçalvesD. YukuyamaM.N. MiyagiM.Y.S. Revisiting flubendazole through nanocrystal technology: Statistical design, characterization and its potential inhibitory effect on xenografted lung tumor progression in mice.J. Cluster Sci.2022202211210.1007/s10876‑022‑02220‑x
     [Google Scholar]
  21. XieX. CaiX. TangY. Flubendazole elicits antitumor effects by inhibiting STAT3 and activating autophagy in non-small cell lung cancer.Front. Cell Dev. Biol.2021968060010.3389/fcell.2021.680600 34513827
     [Google Scholar]
  22. YukuyamaM.N. GuimaraesL.M.F. SegoviaR.S. Malignant wound - The influence of oil components in flubendazole-loaded nanoemulsions in A549 lung cancer xenograft-bearing mice.J. Drug Deliv. Sci. Technol.20227810396310.1016/j.jddst.2022.103963
     [Google Scholar]
  23. SasakiJ. RameshR. ChadaS. GomyoY. RothJ.A. MukhopadhyayT. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells.Mol. Cancer Ther.200211312011209 12479701
     [Google Scholar]
  24. MukhopadhyayT. SasakiJ. RameshR. RothJ.A. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo.Clin. Cancer Res.20028929632969 12231542
     [Google Scholar]
  25. LiangZ. ChenQ. PanL. SheX. ChenT. Mebendazole induces apoptosis and inhibits migration via the reactive oxygen species-mediated STAT3 signaling downregulation in non-small cell lung cancer.J. Thorac. Dis.20241621412142310.21037/jtd‑23‑1978 38505087
     [Google Scholar]
  26. SongB. ParkE.Y. KimK.J. KiS.H. Repurposing of benzimidazole anthelmintic drugs as cancer therapeutics.Cancers 20221419460110.3390/cancers14194601 36230527
     [Google Scholar]
  27. SonD.S. LeeE.S. AdunyahS.E. The antitumor potentials of benzimidazole anthelmintics as repurposing drugs.Immune Netw.2020204e2910.4110/in.2020.20.e29 32895616
     [Google Scholar]
  28. SatijaG. SharmaB. MadanA. Benzimidazole based derivatives as anticancer agents: Structure activity relationship analysis for various targets.J. Heterocycl. Chem.2022591226610.1002/jhet.4355
     [Google Scholar]
  29. McLoughlinE.C. O’BoyleN.M. Colchicine-binding site inhibitors from chemistry to clinic: A review.Pharmaceuticals2020131810.3390/ph13010008 31947889
     [Google Scholar]
  30. KhattabM. Al-KarmalawyA.A. Revisiting activity of some nocodazole analogues as a potential anticancer drugs using molecular docking and DFT calculations.Front Chem.2021962839810.3389/fchem.2021.628398 33842429
     [Google Scholar]
  31. ShimomuraI. YokoiA. KohamaI. Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer.Cancer Lett.2019451112210.1016/j.canlet.2019.03.002 30862488
     [Google Scholar]
  32. XuD. TianW. JiangC. HuangZ. ZhengS. The anthelmintic agent oxfendazole inhibits cell growth in non small cell lung cancer by suppressing c Src activation.Mol. Med. Rep.20191942921292610.3892/mmr.2019.9897 30720086
     [Google Scholar]
  33. ElmaatyA.A. DarwishK.M. ChroudaA. In silico and in vitro studies for benzimidazole anthelmintics repurposing as VEGFR-2 antagonists: Novel mebendazole-loaded mixed micelles with enhanced dissolution and anticancer activity.ACS Omega20217187589910.1021/acsomega.1c05519 35036753
     [Google Scholar]
  34. KhattabM. Al-KarmalawyA.A. Computational repurposing of benzimidazole anthelmintic drugs as potential colchicine binding site inhibitors.Future Med. Chem.202113191623163810.4155/fmc‑2020‑0273 34505541
     [Google Scholar]
  35. FlorioR. CarradoriS. VeschiS. Screening of benzimidazole-based anthelmintics and their enantiomers as repurposed drug candidates in cancer therapy.Pharmaceuticals202114437210.3390/ph14040372 33920661
     [Google Scholar]
  36. ArmandoR.G. Mengual GómezD.L. GomezD.E. New drugs are not enough drug repositioning in oncology: An update.Int. J. Oncol.202056365168410.3892/ijo.2020.4966 32124955
     [Google Scholar]
  37. Hossein PourgholamiM. Yan CaiZ. LuY. WangL. Lawson MorrisD. Albendazole: A potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.Clin. Cancer Res.20061261928193510.1158/1078‑0432.CCR‑05‑1181 16551879
     [Google Scholar]
  38. HoveiziE. JahromiF.F. Cytotoxic effects of flubendazole in human lung cancer cell line A549.Jentashapir J Cell Mol Biol2020114e10892310.5812/jjcmb.108923
     [Google Scholar]
  39. CoyneC.P. NarayananL. Mebendazole in simultaneous combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR] generated utilizing a novel synthesis regimen: Dual anti-neoplastic cytotoxicity against pulmonary adenocarcinoma (A549).J. Exp. Ther. Oncol.201913281118 31881126
     [Google Scholar]
/content/journals/cds/10.2174/0115748863308476240702053700
Loading
A Systematic Review of the Impact of Benzimidazole-based Anthelmintics on Lung Cancer in Animal Models
Curr Drug Saf 20, 303 (2025); https://doi.org/10.2174/0115748863308476240702053700
/content/journals/cds/10.2174/0115748863308476240702053700
/content/journals/cds/10.2174/0115748863308476240702053700
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): animal models; Anticancer; benzimidazole-based anthelmintics; efficacy; lung cancer; non-small cell lung carcinoma; NSCLC; preclinical; safety; systematic review

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test